Bluejay Diagnostics shares are trading lower after the company priced its public offering.
$BJDX
Medical/Dental Instruments
Health Care
Bluejay Diagnostics shares are trading lower after the company priced its public offering.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2022 | $10.00 | Buy | Dawson James |
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, "BJDX.
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock ("Common Stock") or one pre-funded warrant to purchase
ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consists of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company's common stock ("Common Stock") or one pre-funded warrant to purchase
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)
8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.
ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa